EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.

Abstract

Osteoporosis and the resulting fractures are major public health issues as the world population is ageing. Various therapies such as bisphosphonates, strontium ranelate and more recently denosumab are available. This clinical guide provides the evidence for the clinical use of selective estrogen modulators (SERMs) in the management of osteoporosis in postmenopausal women.

• Authors: Santiago Palacios, Mark Brincat, C Tamer Erel, Marco Gambacciani, Irene Lambrinoudaki, Mette H Moen, Karin Schenck-Gustafsson, Florence Tremollieres, Svetlana Vujovic, Margaret Rees, Serge Rozenberg
• Journal: Maturitas (Maturitas) Vol. 71 Issue 2 Pg. 194-8 (Feb 2012) ISSN: 1873-4111 [Electronic] Ireland
• PMID: 22176952 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bone Density Conservation Agents
• Diphosphonates
• Organometallic Compounds
• Selective Estrogen Receptor Modulators
• Thiophenes
• strontium ranelate
• Denosumab

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bone Density Conservation Agents (therapeutic use)
• Denosumab
• Diphosphonates (therapeutic use)
• Female
• Fractures, Bone (prevention & control)
• Humans
• Organometallic Compounds (therapeutic use)
• Osteoporosis, Postmenopausal (drug therapy)
• Selective Estrogen Receptor Modulators (therapeutic use)
• Thiophenes (therapeutic use)